Orexigen Therapeutics, Inc. 4
4 · Orexigen Therapeutics, Inc. · Filed Jun 2, 2016
Insider Transaction Report
Form 4
Cannell Thomas R
Chief Commercial Officer
Transactions
- Award
Common Stock
2016-05-31$0.34/sh+9,632$3,275→ 14,723 total
Footnotes (1)
- [F1]Shares acquired under Issuer's 2013 Employee Stock Purchase Plan.